Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Net Income (2020 - 2025)

Historic Net Income for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to -$7.6 million.

  • GeneDx Holdings' Net Income rose 814.49% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 10249.55%. This contributed to the annual value of -$52.3 million for FY2024, which is 7025.27% up from last year.
  • GeneDx Holdings' Net Income amounted to -$7.6 million in Q3 2025, which was up 814.49% from $10.8 million recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Net Income ranged from a high of $32.7 million in Q3 2021 and a low of -$308.7 million during Q4 2022
  • Its 5-year average for Net Income is -$54.0 million, with a median of -$40.2 million in 2021.
  • As far as peak fluctuations go, GeneDx Holdings' Net Income soared by 15781.33% in 2021, and later plummeted by 66822.94% in 2022.
  • Quarter analysis of 5 years shows GeneDx Holdings' Net Income stood at -$40.2 million in 2021, then crashed by 668.23% to -$308.7 million in 2022, then skyrocketed by 91.65% to -$25.8 million in 2023, then skyrocketed by 121.1% to $5.4 million in 2024, then plummeted by 240.4% to -$7.6 million in 2025.
  • Its Net Income stands at -$7.6 million for Q3 2025, versus $10.8 million for Q2 2025 and -$6.5 million for Q1 2025.